Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2015

View Archived Issues

Alios Biopharma starts first-in-human study of HCV polymerase inhibitor AL-704

Novavax reports data from phase II trial of quadrivalent seasonal influenza vaccine

arGEN-X and University of Bern to develop ARGX-110-based combination therapies

University of Sydney to study Cymerus stem cells in heart disease models

Heptares to use MorphoSys antibody discovery technology against GPCR target

D-Pharm reports results from pilot trial of DP-b99 in acute pancreatitis

Filgotinib meets key efficacy endpoints in phase IIb DARWIN 1 study

Eisai and Halozyme sign collaboration agreement to investigate eribulin and PEGPH-20

Beijing Normal University patents technetium complexes for imaging

Coferon discloses Bcr-Abl tyrosine-kinase ligands

FDA accepts IND for EDO-S101 in patients with hematologic malignancies and solid tumors

KannaLife Sciences describes neuroprotectants

Aurigene Discovery Technologies divulges IRAK-4 inhibitors

KT&G Life Sciences develops NQO1 modulators

Alios Biopharma starts phase I drug interaction study for AL-335

AstraZeneca and Isis Pharmaceuticals form second antisense therapy collaboration

Sanofi profiles pipeline progress of second quarter 2015

Novel apelin receptor agonist shows promise as vasodilator

Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer

CTLA4-targeted therapies show promise for the treatment of LRBA deficiency

Allergan's AGN-223575 enters phase II study in dry eye

Biocad initiates phase I trial comparing adalimumab biosimilar to Humira

Anti-GD2 antibody enters phase II trial in osteosarcoma

TiGenix acquires Coretherapix

ORAI1 inhibitors show potential for the treatment of pancreatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...